149 related articles for article (PubMed ID: 10960060)
1. Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the rat.
Burke BE; Gambliel H; Olson RD; Bauer FK; Cusack BJ
Br J Pharmacol; 2000 Sep; 131(1):1-4. PubMed ID: 10960060
[TBL] [Abstract][Full Text] [Related]
2. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
[TBL] [Abstract][Full Text] [Related]
3. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M
Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762
[TBL] [Abstract][Full Text] [Related]
4. Persistent effects of doxorubicin on cardiac gene expression.
Boucek RJ; Miracle A; Anderson M; Engelman R; Atkinson J; Dodd DA
J Mol Cell Cardiol; 1999 Aug; 31(8):1435-46. PubMed ID: 10423342
[TBL] [Abstract][Full Text] [Related]
5. Cholinesterases in dexrazoxane-treated daunorubicin cardiomyopathy in rabbits.
Gersl V; Bajgar J; Hrdina R; Mazurová Y; Machácková J; Cerman J; Suba P
Gen Physiol Biophys; 1999 Dec; 18(4):335-46. PubMed ID: 10766032
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
7. Treatment of anthracycline extravasation with dexrazoxane.
Langer SW; Sehested M; Jensen PB
Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
[TBL] [Abstract][Full Text] [Related]
8. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
[TBL] [Abstract][Full Text] [Related]
9. Effect of sodium 2,3-dimercaptopropane-1-sulphonate (DMPS) on chronic daunorubicin toxicity in rabbits: comparison with dexrazoxane.
Hrdina R; Gersl V; Klimtová I; Simůnek T; Mazurová Y; Machácková J; Adamcová M
Acta Medica (Hradec Kralove); 2002; 45(3):99-105. PubMed ID: 12515046
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression.
Gambliel HA; Burke BE; Cusack BJ; Walsh GM; Zhang YL; Mushlin PS; Olson RD
Biochem Biophys Res Commun; 2002 Mar; 291(3):433-8. PubMed ID: 11855807
[TBL] [Abstract][Full Text] [Related]
11. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
Anderson B
Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
[TBL] [Abstract][Full Text] [Related]
12. Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits.
Arai M; Tomaru K; Takizawa T; Sekiguchi K; Yokoyama T; Suzuki T; Nagai R
J Mol Cell Cardiol; 1998 Feb; 30(2):243-54. PubMed ID: 9515001
[TBL] [Abstract][Full Text] [Related]
13. Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits.
Adamcová M; Potáčová A; Popelová O; Štěrba M; Mazurová Y; Aupperle H; Geršl V
Physiol Res; 2010; 59(5):831-836. PubMed ID: 20406046
[TBL] [Abstract][Full Text] [Related]
14. Multiple actions of the anthracycline daunorubicin on cardiac ryanodine receptors.
Hanna AD; Janczura M; Cho E; Dulhunty AF; Beard NA
Mol Pharmacol; 2011 Sep; 80(3):538-49. PubMed ID: 21697274
[TBL] [Abstract][Full Text] [Related]
15. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
Hofland KF; Thougaard AV; Sehested M; Jensen PB
Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
[TBL] [Abstract][Full Text] [Related]
16. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
[TBL] [Abstract][Full Text] [Related]
17. Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart.
Plandé J; Platel D; Tariosse L; Robert J
Toxicol Lett; 2006 Feb; 161(1):37-42. PubMed ID: 16129573
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotective effects of hydroxysafflor yellow A on diabetic cardiac insufficiency attributed to up-regulation of the expression of intracellular calcium handling proteins of sarcoplasmic reticulum in rats.
He H; Liu Q; Shi M; Zeng X; Yang J; Wu L; Li L
Phytother Res; 2008 Aug; 22(8):1107-14. PubMed ID: 18570267
[TBL] [Abstract][Full Text] [Related]
19. Long-lasting effect of dexrazoxane against anthracycline cardiotoxicity in rats.
Della Torre P; Podesta A; Pinciroli G; Iatropoulos MJ; Mazué G
Toxicol Pathol; 1996; 24(4):398-402. PubMed ID: 8864181
[TBL] [Abstract][Full Text] [Related]
20. Enalaprilat increases PPARβ/δ expression, without influence on PPARα and PPARγ, and modulate cardiac function in sub-acute model of daunorubicin-induced cardiomyopathy.
Cernecka H; Ochodnicka-Mackovicova K; Kucerova D; Kmecova J; Nemcekova V; Doka G; Kyselovic J; Krenek P; Ochodnicky P; Klimas J
Eur J Pharmacol; 2013 Aug; 714(1-3):472-7. PubMed ID: 23834779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
